Royal College of Physicians

Royal College of Physicians
[redacted]
Tel: [redacted]

www.rcplondon.ac.uk

c/o
tacommc@nice.org.uk

From [redacted]

6 January 2015

Dear Sir or Madam

Re: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia [ID650] - Appraisal Consultation Document (ACD)

I write on behalf of the NCRI/RCP/ACP to thank you for the opportunity to respond to the above ACD. Our experts have reviewed the document and would like to make the following comments.

We believe that the proposal to split the patient population into those for whom a bendamustine based regimen is a potentially suitable alternative therapy to chlorambucil/obinutuzumab combination therapy and those for whom bendamustine is not appropriate, appears very sensible. This is in keeping with real life physicians thought processes when trying to decide the most appropriate therapy for any individual patient.

We note that NICE have accepted the revised costs for neutropenic fever management.

We note that the company have provided NICE with details of a Patient Access Scheme which they will make available to increase patient access to chlorambucil/obinutuzumab combination therapy.

Our experts do not feel qualified to comment on the various points of disagreement, in terms of the most appropriate utility value to apply to the various scenarios examined with regards to PFS.

We note in the ACD that the Committee are recommending the use of chlorambucil/obinutuzumab for patients unsuitable for a bendamustine based regimen but not for those patients suitable for a bendamustine based regimen providing that the PAS is supplied by the company. We believe that this is an appropriate recommendation as it gives patients with few other therapeutic options the opportunity of receiving chrlorambucil/obinutuzumab, which will prolong their survival. Our experts feel that this recommendation, if accepted, will also enable clinicians the full range of appropriate therapeutic options to their very heterogeneous CLL patients.

In conclusion, we support the recommendations regarding the provision of chlorambucil/obinutuzumab combination therapy to CLL patients as outlined in the Appraisal Consultation Document

Yours faithfully

[redacted]

[redacted]